Victrelis Treat Chronic Hepatitis C

INSTITUTIONS American Food and Drug Administration (FDA) approved a new drug called Victrelis (boceprevir) to treat patients with chronic hepatitis C in adults. "Victrelis is used for patients with some heart fungsung can still work and have not been treated withdrug therapy for hepatitis C or who have failed treatment, "explains the release of the FDA, as quoted by WebMD site.

FDA Approves Victrelis for use with standard hepatitis C treatments. Victrelis drugapproval is based on two studies of 1,500 adult patients with hepatitis C. In the study, twothirds of the number of patients receiving Victrelis in combination with two standardhepatitis C drugs The result of hepatitis C virus was not detected in their blood after 24weeks of treatment was stopped.

"Victrelis is a new advancement for patients with hepatitis C. These new drugs provideeffective treatments for serious diseases. It offers greater opportunities for some patientsto hepatitis C infection compared to currently available therapies," said Edward Cox, MD,MPH in an FDA news release. Cox himself led the Office of Antimicrobial Products at the FDA Center for Drug Evaluation and Research.

Victrelis the form of pills taken three times daily with food. This therapy was part of a class of drugs called protease inhibitors, which work binding the virus and prevent it developing.

In a recent study by the FDA, the most frequent side effects reported in patients receivingVictrelis are fatigue, the number of low red blood cells (anemia), nausea, headaches, and the distortion of flavors.